Find out how AI influences drug discovery, enabling earlier predictions and reducing the risks in clinical development.

Illumina, Inc. (NASDAQ: ILMN) today introduced the world's largest genome-wide genetic perturbation dataset, being built to ...

On January 9, 2026, the latest edition of Applied Artificial Intelligence for Drug Discovery was published online as a Springer Nature volume, spanning 27 chapters authored by leading international ...

Explore the role of transcription factor biology in drug discovery and how it impacts our understanding of disease mechanisms ...

SAN DIEGO--(BUSINESS WIRE)--Sapient, a leader in multi-omics data generation for biomarker discovery and clinical insight delivery, has launched the next generation of its multi-omics and real-world ...

Illumina unveiled the Billion Cell Atlas, a large‑scale genetic perturbation dataset built with pharma partners to advance AI‑powered drug discovery, target validation, and disease biology.

OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5 M seed funding round. The Company ...

Large language models (LLMs) can be broadly applied across multiple key stages in drug development: (1) Target identification and drug screening. Llama-Gram, GPCR LLM, and ProtChat systems effectively ...

Zhongyao Ma, PhD, holds a bachelor’s degree in biology from Shanghai Jiao Tong University and a PhD in genetics and developmental biology from the University of Georgia, U.S. His research focused on ...

According to MarketsandMarkets™, the Drug Discovery Technologies Market is projected to grow from about USD 30.58 billion in ...